Adaptive Biotechnologies Corporation Stock
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | -4.62% | -15.38% | -32.65% |
Financials (USD)
Sales 2024 * | 169M | Sales 2025 * | 207M | Capitalization | 486M |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -148M | EV / Sales 2024 * | 2.79 x |
Net cash position 2024 * | 14.91M | Net cash position 2025 * | 7.88M | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
-2.57
x | P/E ratio 2025 * |
-3.14
x | Employees | 709 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.9% |
Latest transcript on Adaptive Biotechnologies Corporation
1 day | -4.62% | ||
1 week | -15.38% | ||
Current month | -4.35% | ||
1 month | -13.16% | ||
3 months | -3.23% | ||
6 months | -33.47% | ||
Current year | -32.65% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Kyle Piskel
DFI | Director of Finance/CFO | 40 | 21-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-13 | 3.3 | -4.62% | 647,380 |
24-06-12 | 3.46 | +0.29% | 870,387 |
24-06-11 | 3.45 | -1.15% | 787,596 |
24-06-10 | 3.49 | -3.32% | 1,422,951 |
24-06-07 | 3.61 | -7.44% | 1,449,572 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.65% | 486M | |
-42.21% | 7.89B | |
+16.49% | 3.86B | |
+3.69% | 2.36B | |
-20.58% | 2B | |
-20.79% | 1.67B | |
+18.47% | 1.03B | |
+21.75% | 761M | |
-9.61% | 693M | |
-9.24% | 266M |
- Stock Market
- Equities
- ADPT Stock